Announcements Trials
Browse Landscape

Phase

Phase 2 63Phase 1/2 24Phase 1 23Phase 3 9Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Recruiting 4Not yet recruiting 3Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Azacitidine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Recruiting
40 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05939180 2024-04-09

VA vs DA for Newly Diagnosed Hig-risk AML

The First Affiliated Hospital of Soochow University

Phase 2/3 Recruiting
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05404906 2022-08-19

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

The First Affiliated Hospital of Soochow University

Phase 2/3 Recruiting
124 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡